ABP 234

DRUG2 trials

Sponsors

Amgen

Conditions

Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Active, not recruitingNCT06311721

AmgenAdvanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Start: 2024-09-09End: 2028-04-24Updated: 2026-05-06

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Active, not recruitingNCT06430866

AmgenEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Start: 2024-09-12End: 2026-12-14Updated: 2026-04-01